select
patient
acquisit
sampl
etiolog
acut
exacerb
idiopath
pulmonari
fibrosi
remain
unknown
occult
viral
infect
propos
one
possibl
caus
acut
exacerb
idiopath
pulmonari
fibrosi
studi
use
current
genomicsbas
technolog
investig
possibl
infecti
etiolog
acut
exacerb
idiopath
pulmonari
fibrosi
case
demonstr
evid
viral
infect
torqu
teno
viru
present
signific
minor
case
case
acut
lung
injuri
rational
idiopath
pulmonari
fibrosi
progress
uniformli
fatal
interstiti
lung
diseas
acut
exacerb
idiopath
pulmonari
fibrosi
episod
acut
respiratori
worsen
without
identifi
etiolog
occult
viral
infect
propos
possibl
caus
acut
exacerb
object
use
unbias
genomicsbas
discoveri
method
defin
role
virus
acut
exacerb
idiopath
pulmonari
fibrosi
method
bronchoalveolar
lavag
serum
patient
acut
exacerb
idiopath
pulmonari
fibrosi
stabl
diseas
acut
lung
injuri
test
viral
nucleic
acid
use
multiplex
polymeras
chain
reaction
panvir
microarray
highthroughput
cdna
sequenc
measur
main
result
four
fortythre
patient
acut
exacerb
idiopath
pulmonari
fibrosi
evid
common
respiratori
viral
infect
parainfluenza
patient
acut
exacerb
ttv
infect
significantli
common
patient
acut
exacerb
stabl
control
p
present
similar
percentag
acut
lung
injuri
control
deep
sequenc
subset
acut
exacerb
case
confirm
presenc
ttv
identifi
addit
virus
conclus
viral
infect
detect
case
acut
exacerb
idiopath
pulmonari
fibrosi
ttv
present
signific
minor
case
case
acut
lung
injuri
clinic
signific
find
remain
determin
keyword
acut
lung
injuri
viru
infect
pulmonari
fibrosi
etiolog
idiopath
pulmonari
fibrosi
ipf
progress
fibrot
lung
diseas
known
caus
cure
although
patient
experi
steadi
progress
diseas
time
mani
period
rel
stabil
punctuat
episod
acut
respiratori
worsen
fatal
identifi
caus
acut
worsen
found
term
acut
exacerb
ipf
acut
exacerb
ipf
defin
idiopath
acut
worsen
dyspnea
character
radiolog
presenc
bilater
ground
glass
abnorm
highresolut
comput
tomographi
scan
chest
estim
patient
ipf
experi
acut
exacerb
annual
physiolog
advanc
diseas
higher
risk
remain
unclear
whether
acut
exacerb
ipf
repres
primari
acceler
underli
fibroprolif
process
ipf
clinic
occult
secondari
complic
eg
infect
acut
exacerb
ipf
often
accompani
fever
increas
cough
myalgia
suggest
infecti
etiolog
respiratori
virus
consid
particularli
like
caus
base
similar
clinic
radiolog
present
acut
exacerb
ipf
viral
pneumon
poor
sensit
standard
method
viral
detect
also
may
increas
incid
acut
exacerb
ipf
east
asia
find
could
explain
environment
factor
endem
viru
preliminari
evalu
role
infect
acut
exacerb
yield
mix
result
studi
test
hypothesi
acut
exacerb
ipf
caus
occult
viral
infect
prospect
collect
bronchoalveolar
lavag
bal
patient
experienc
acut
exacerb
ipf
control
stabl
ipf
acut
lung
injuri
ali
use
multiplex
polymeras
chain
reaction
pcr
panvir
microarray
discoveri
platform
test
presenc
known
novel
virus
nextgener
parallel
sequenc
deep
sequenc
appli
subset
acut
exacerb
sampl
increas
sensit
viral
detect
patient
acut
exacerb
ipf
identifi
prospect
two
center
univers
ulsan
korea
tosei
gener
hospit
japan
sequenti
subject
acut
exacerb
ipf
enrol
underw
bronchoscopi
consent
diagnost
criteria
acut
exacerb
ipf
prespecifi
accord
establish
criteria
patient
acut
exacerb
neg
clinic
evalu
infecti
caus
includ
routin
bacteri
viral
bal
antibodi
titer
cultur
respiratori
syncyti
viru
influenza
b
human
parainfluenza
virus
adenoviru
human
cytomegaloviru
cmv
herp
simplex
viru
hsv
varicellazost
viru
control
patient
stabl
ipf
defin
absenc
acut
exacerb
ali
identifi
exist
cohort
singl
center
univers
ulsan
korea
underw
bronchoscopi
time
diagnosi
ipf
ali
defin
consensu
criteria
bal
case
ipf
posit
rhinoviru
cmv
includ
blind
posit
control
center
receiv
approv
institut
review
board
equival
patient
provid
inform
consent
case
bronchoscopi
perform
part
patient
clinic
evalu
case
bal
collect
within
first
hour
admiss
hospit
gener
bal
perform
singl
subseg
right
middl
lobe
lingula
least
ml
steril
salin
instil
blood
collect
part
initi
studi
protocol
subset
acut
exacerb
sampl
stabl
ipf
control
underw
phlebotomi
time
bronchoscopi
part
separ
ongo
repositori
studi
sampl
avail
us
analysi
sampl
store
c
readi
process
total
rna
extract
ml
sampl
use
rneasi
mini
kit
qiagen
inc
valencia
ca
accord
manufactur
instruct
blind
nest
respiratori
multiplex
pcr
run
bal
sampl
acut
exacerb
ipf
stabl
ipf
control
prespecifi
respiratori
virus
influenza
viru
human
parainfluenza
viru
respiratori
syncyti
viru
human
rhinoviru
human
enteroviru
human
coronaviru
human
metapneumoviru
human
adenoviru
pcr
also
perform
confirm
viral
signatur
present
panvir
microarray
analysi
hsv
epsteinbarr
viru
torqu
teno
viru
ttv
use
publish
nest
primer
set
addit
pcr
ttv
perform
bal
sampl
ali
control
serum
sampl
subset
acut
exacerb
ipf
stabl
ipf
control
defin
better
epidemiolog
ttv
acut
exacerb
ipf
sampl
stabl
ipf
control
randomli
amplifi
gener
cdna
hybrid
blindli
panvir
microarray
previous
describ
array
scan
use
axon
scanner
molecular
devic
sunnyval
ca
intens
calcul
use
genepix
molecular
devic
presenc
viral
signatur
determin
use
cluster
epredict
microarray
data
deposit
gene
express
omnibu
geo
access
bal
subgroup
studi
patient
acut
exacerb
ipf
select
deep
sequenc
illumina
genom
analyz
iix
platform
illumina
san
diego
ca
base
presenc
fever
myalgia
symptom
suggest
virallik
ill
deep
sequenc
librari
prepar
analyz
describ
onlin
supplement
deep
sequenc
read
submit
short
read
archiv
sra
access
clinic
data
express
mean
percentag
unless
otherwis
state
primari
comparison
bal
sampl
acut
exacerb
ipf
stabl
ipf
control
addit
comparison
made
bal
sampl
acut
exacerb
ipf
ali
control
serum
sampl
acut
exacerb
ipf
stabl
ipf
control
case
intergroup
comparison
perform
conserv
use
nonparametr
method
wilcoxon
signedrank
test
chisquarefish
exact
analys
appropri
regress
analysi
perform
determin
relationship
clinic
factor
pcr
posit
surviv
clinic
data
analysi
perform
use
sa
sa
institut
cari
nc
statist
signific
defin
p
valu
less
sixti
patient
acut
exacerb
ipf
korean
japanes
identifi
fortythre
underw
bronchoscopi
enrol
studi
median
time
diagnosi
acut
exacerb
day
clinic
characterist
summar
tabl
twelv
acut
exacerb
patient
ipf
present
fever
myalgia
suggest
virallik
ill
forti
patient
stabl
ipf
twentynin
patient
ali
includ
control
patient
ali
predominantli
lower
respiratori
tract
infect
underli
caus
lung
injuri
patient
mechan
ventil
mean
pao
fio
ratio
serum
avail
acut
exacerb
patient
ipf
stabl
ipf
control
four
acut
exacerb
ipf
bal
sampl
posit
common
respiratori
virus
initi
multiplex
pcr
two
rhinoviru
one
human
one
parainfluenza
stabl
ipf
sampl
neg
common
respiratori
virus
p
compar
acut
exacerb
ipf
sampl
tabl
array
analysi
acut
exacerb
ipf
bal
sampl
reveal
presenc
immunosuppress
therapi
includ
corticosteroid
without
immunomodul
therapi
ttv
sever
human
herpesvirus
accur
identifi
rhinoviru
cmv
known
posit
control
pursu
find
perform
sensit
genomespecif
pcr
reaction
hsv
epsteinbarr
viru
ttv
yield
addit
bal
posit
acut
exacerb
ipf
sampl
tabl
addit
virus
ttv
significantli
common
acut
exacerb
ipf
compar
stabl
control
vs
p
four
bal
sampl
reveal
doubl
infect
two
ttv
rhinoviru
one
ttv
parainfluenza
one
ttv
hsv
one
bal
sampl
reveal
tripl
infect
ttv
epsteinbarr
viru
coronaviru
overal
acut
exacerb
ipf
sampl
posit
viru
compar
posit
stabl
ipf
sampl
p
differ
frequenc
fever
myalgia
virusposit
virusneg
case
signific
differ
use
corticosteroid
treatment
bal
studi
patient
acut
exacerb
ipf
select
deep
sequenc
investig
possibl
virus
present
undetect
pcr
microarray
sampl
two
pcrposit
test
virus
one
ttv
one
ttv
hsv
initi
qualiti
filter
approxim
million
pair
million
total
read
compris
primari
dataset
barcod
acut
exacerb
ipf
sampl
repres
least
million
highqual
read
read
deriv
human
origin
remain
read
approxim
recogniz
bacteri
origin
hundr
potenti
attribut
known
nonhuman
eukaryot
virus
asid
bacteriophag
three
virus
two
ttv
one
hsv
found
consist
pcr
result
stage
map
sequenc
databas
finish
approxim
origin
dataset
remain
without
attribut
comparison
ttvposit
ttvneg
acut
exacerb
ipf
sampl
signific
differ
age
sex
baselin
pulmonari
function
time
bronchoscopi
ttvposit
acut
exacerb
ofpati
ipf
compar
ttvneg
acut
exacerb
ipf
patient
data
shown
patient
ttv
posit
appear
sicker
requir
mechan
ventil
vs
patient
ttv
neg
p
die
day
vs
patient
ttv
neg
p
overal
median
surviv
time
patient
ttv
posit
day
vs
patient
ttv
neg
p
figur
bivari
regress
analysi
potenti
independ
predictor
surviv
time
presenc
absenc
prednison
treatment
time
bal
mechan
ventil
time
bal
ttv
posit
bal
reveal
mechan
ventil
statist
signific
hazard
ratio
p
ttv
posit
independ
predictor
surviv
time
hazard
ratio
p
total
patient
acut
exacerb
ipf
pcr
posit
ttv
serum
compar
patient
stabl
ipf
p
relationship
serum
bal
posit
three
six
patient
acut
exacerb
pcr
posit
serum
also
pcr
posit
bal
four
patient
acut
exacerb
pcr
neg
serum
pcr
posit
bal
statist
signific
link
balassoci
ttv
acut
exacerb
ipf
prompt
us
also
examin
bal
sampl
patient
ali
ttv
detect
bal
sampl
ali
patient
significantli
differ
preval
ttv
bal
sampl
acut
exacerb
ipf
p
use
highli
sensit
pcr
panvir
microarray
deep
sequenc
technolog
larg
welldescrib
cohort
patient
acut
exacerb
ipf
control
found
case
acut
exacerb
ipf
evid
underli
viral
infect
suggest
viral
infect
common
caus
acut
exacerb
ipf
overal
found
viral
nucleic
acid
bal
patient
acut
exacerb
ipf
virus
found
sampl
stabl
ipf
control
two
rhinovirusposit
sampl
one
coronavirusposit
sampl
one
parainfluenza
virusposit
sampl
suggest
small
minor
acut
exacerb
ipf
may
caus
occult
infect
common
respiratori
virus
surprisingli
common
viru
detect
bal
acut
exacerb
ipf
patient
ttv
present
acut
exacerb
bal
sampl
find
uniqu
acut
exacerb
ipf
bal
sampl
ali
control
also
ttv
posit
two
recent
studi
comment
indirectli
possibl
role
occult
viral
infect
acut
exacerb
ipf
first
studi
perform
gene
express
microarray
whole
lung
tissu
patient
die
acut
exacerb
ipf
patient
stabl
ipf
healthi
control
author
conclud
acut
exacerb
ipf
character
pattern
enhanc
epitheli
injuri
prolifer
found
gene
express
profil
indic
respons
viral
bacteri
infect
second
studi
patient
present
acut
declin
fibrot
lung
diseas
confirm
acut
exacerb
ipf
antigen
pcr
evid
viral
infect
one
parainfluenza
viru
two
hsv
two
cmv
infect
three
miss
standard
viral
cultur
studi
expand
significantli
previous
publish
report
first
take
unbias
approach
viral
discoveri
use
cuttingedg
genom
methodolog
first
studi
acut
exacerb
ipf
use
sequenc
confirm
suspect
virus
rule
possibl
spuriou
pcr
result
common
pitfal
techniqu
second
larg
cohort
welldefin
patient
acut
exacerb
adequ
control
allow
greater
certainti
regard
conclus
third
identifi
unexpect
viru
ttv
associ
acut
exacerb
absent
stabl
ipf
pathogenet
signific
ttv
acut
exacerb
ipf
bal
unclear
ttv
nonenvelop
singlestrand
circular
dna
viru
exist
genet
divers
clade
viru
seem
broad
tissu
tropism
detect
peripher
blood
mononuclear
cell
pbmc
bone
marrow
spleen
liver
lung
infect
ttv
human
popul
worldwid
preval
viremia
rang
depend
popul
studi
detect
methodolog
use
consid
heminest
pcr
region
use
studi
rate
ttv
dna
found
healthi
blood
donor
rang
seem
correl
geograph
locat
patient
infect
subject
asymptomat
date
effort
link
ttv
viremia
acut
chronic
patholog
state
unsuccess
although
report
ttv
upper
respiratori
tract
nasopharynx
oral
caviti
ttv
identifi
bal
fluid
ttv
previous
detect
serum
japanes
patient
ipf
studi
ttv
appear
frequent
case
progress
acut
exacerb
ttv
posit
suggest
correl
wors
surviv
find
show
correl
presenc
ttv
serum
presenc
ttv
bal
correl
serum
ttv
posit
diagnosi
acut
exacerb
possibl
de
novo
ttv
infect
lung
caus
direct
alveolar
epitheli
cell
injuri
acut
respiratori
worsen
process
seem
uniqu
acut
exacerb
ipf
detect
ttv
similar
frequenc
bal
patient
ali
although
exclud
potenti
role
ttv
pathogenesi
acut
exacerb
ipf
also
compat
idea
inflamm
injuri
lung
may
nonspecif
trigger
local
ttv
replic
may
result
increas
vascular
permeabl
lung
allow
circul
viru
enter
alveolar
compart
latter
two
case
presenc
ttv
would
repres
consequ
lung
inflamm
rather
caus
idea
local
ttv
replic
might
enhanc
underli
inflammatori
signal
support
vitro
studi
pbmc
donor
ttv
neg
pbmc
infect
vitro
ttv
cultur
without
presenc
phytohemagglutinin
lipopolysaccharid
examin
evid
ttv
replic
experi
ttv
mrna
replic
intermedi
found
stimul
pbmc
consist
infectionamplifi
role
inflammatori
signal
methodolog
use
studi
unparallel
sensit
viral
detect
multiplex
nest
pcr
sever
fold
sensit
viru
cultur
direct
immunofluoresc
test
abil
amplifi
less
copi
target
nucleic
acid
viral
discoveri
howev
pcr
limit
use
identifi
priori
viral
target
panvir
microarray
preclud
need
preconceiv
list
target
although
even
prove
sensit
benefit
depend
signaltonois
ratio
nucleic
acid
use
deep
sequenc
look
evid
viral
infect
highrisk
subpopul
patient
acut
exacerb
therefor
add
confid
result
produc
unbias
highresolut
descript
microbi
landscap
sampl
test
technolog
use
identifi
novel
virus
human
diarrhea
describ
microbiom
distal
gut
never
bal
current
studi
two
sampl
subject
deep
sequenc
posit
known
virus
pcr
panvir
array
screen
use
effici
sensit
pipelin
sort
read
posit
pcr
find
confirm
addit
virus
detect
sampl
test
interpret
find
must
temper
fact
exist
comput
method
recogn
potenti
viral
genom
imperfect
may
fail
identifi
novel
agent
limit
homolog
known
viral
genera
true
arraybas
viral
detect
method
one
import
limit
studi
potenti
falseneg
result
time
sampl
collect
bal
perform
earli
cours
hospit
commonli
first
hour
admiss
median
time
symptom
onset
sampl
day
importantli
differ
time
symptom
onset
sampl
collect
found
virusposit
virusneg
case
durat
replic
viru
bal
larg
unknown
possibl
viru
could
stop
shed
time
studi
maxim
likelihood
detect
viru
obtain
bal
sampl
earli
admiss
use
highli
sensit
viral
detect
techniqu
summari
studi
use
unbias
highli
sensit
genomicsbas
discoveri
method
investig
role
viral
infect
larg
wellcharacter
cohort
patient
acut
exacerb
ipf
result
studi
suggest
case
acut
exacerb
ipf
caus
viral
infect
futur
research
etiolog
acut
exacerb
ipf
confirm
find
investig
role
ttv
consid
possibl
occult
complic
eg
aspir
may
caus
acut
respiratori
worsen
patient
author
disclosur
scw
financi
relationship
commerci
entiti
interest
subject
manuscript
dsk
financi
relationship
commerci
entiti
interest
subject
manuscript
yk
financi
relationship
commerci
entiti
interest
subject
manuscript
ec
receiv
fund
chui
lab
abbott
diagnost
jsl
financi
relationship
commerci
entiti
interest
subject
manuscript
jw
financi
relationship
commerci
entiti
interest
subject
manuscript
jwh
financi
relationship
commerci
entiti
interest
subject
manuscript
ht
financi
relationship
commerci
entiti
interest
subject
manuscript
cc
receiv
research
support
abbott
diagnost
hb
board
member
health
effect
institut
consult
pharmaxi
ltd
kalobio
pharmaceut
inc
merck
sharp
dohm
genentech
employ
univers
california
san
francisco
receiv
grant
support
glaxosmithklin
receiv
royalti
mcgrawhil
co
blackwel
publish
ltd
taylor
franci
lhl
advisori
board
intermun
actelion
receiv
grant
support
intermun
actelion
johnson
johnson
gilead
pjw
financi
relationship
commerci
entiti
interest
subject
manuscript
jd
financi
relationship
commerci
entiti
interest
subject
manuscript
dg
financi
relationship
commerci
entiti
interest
subject
manuscript
hrc
institut
receiv
consult
fee
boehringeringelheim
fibrogen
genentech
gilead
actelion
arresto
receiv
institut
grant
support
chest
foundationasp
receiv
payment
develop
educ
present
franc
foundat
